Market Report Source

Overview

Report Overview

Examines the market for addiction pharmacotherapies currently estimated at US$2 billion but forecast to increase 41% CAGR to US$2.9 billion by 2012. Drivers of growth include increasing global prevalence of alcohol, narcotic, and nicotine dependencies and premarket pharmacotherapies to treat methamphetamine, phencyclidine, and gambling addictions. With over 30 drug candidates in the pipeline for addiction disorders, medical therapies for these highly prevalent difficult-to-treat conditions are on course for dynamic change. This report comments on strategic and commercial issues that may affect current product positioning and discusses key compounds such as naltrexone reformulations, nicotine replacement therapies, and novel vaccine therapies that have the potential to create new market sectors and become high-value products over the next decade. The report also provides insights into forthcoming market dynamics and product sales to 2012 to enable the reader to make assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Table of Contents

Objectives of the Report
Research Methodology

Chapter 1 Introduction to Addiction Disorders

Addiction Disorders
Incidence of Addiction Disorders
Neurobiological Basis of Addiction
Treatment Options

Chapter 2 The Addiction Pharmacotherapy Market

Addictions
Market Overview for Addiction Disorders
Market Forecasts by Therapeutic Area
Alcohol Addiction
Narcotic Addiction
Tobacco Addiction
Market Forecasts for Addiction Disorders
Market Analysis of Drugs to Treat Addiction Disorders

Alcohol Addiction
Alcohol Addiction Pharmacotherapies
Acamprosate (Campral) – Merck/Forest Laboratories
Mechanisms of Action/Efficacy
Sales Estimates for Campral
Product Line Extension Possibilities
Disulfiram (Antabuse) – Alpharma
Mechanism of Action/Efficacy
Sales Estimates for Disulfiram
Naltrexone Hydrochlride
Mechanisms of Action/Efficacy
Reformulation – Vivitrex, Alkermes/Cephalon
Sales Estimates for Naltrexone
Pipeline Focus
Naltrexone Depot – Drug Abuse Sciences, France
Nalmefene – BioTie Therapies, Finland
Alcohol Addiction – Market Insights and Future Considerations
Narcotic Addiction Pharmacotherapeutics

Cocaine Addiction
Mechanisms of Action of Cocaine
Future Therapeutics for Cocaine Addiction
Vaccine Therapy Focus – Xenova
COC-AB/DAS-431 – Drug Abuse Sciences

Opiate Addiction
Drug Substitute Therapies
Subutex/Subroxone (Buprenorphine) – Schering-Plough/Reckitt Benckiser
Mechanisms of Action/Efficacy
Reformulation
Sales Estimates
Methadone
Mechanisms of Action/Efficacy
Sales Estimates
Drugs to Control Opiate Withdrawal Symptoms
Brittofex (Lofexidine) – Britannia Pharmaceuticals
Mechanisms of Action/Efficacy
Sales Estimates
Naltrexone
Potential Reformulation
Future Drugs to Treat Opiate Addiction
Probuphine – Titan Pharmaceuticals
Buprenorphine Depot – Drug Abuse Sciences
Narcotic Addiction – Market Insights and Future Considerations
Emerging Drug Addiction Focus
Methamphetamine/Phencyclidine Abuse and Dependency
InterveXion Therapeutics
Outlook for Pharmacotherapeutic Markets Related to Alcohol and
Substance Abuse

Nicotine Addiction
Prevalence and Mortality Statistics
Nicotine – Mechanism of Action
Nicotine Dependency and Smoking Cessation
Smoking and Health Consequences
Healthcare Costs of Smoking Addiction
Nicotine Addiction Pharmacotherapeutics
Market Analysis of Smoking Cessation Pharmacotherapeutics
Nicotine Replacement Therapies
Nicorette/Nicotrol – Pfizer
Sales Estimates
NiQuitin/NicoDerm/Nicorette/Nicabate – GlaxoSmithKline
Sales Estimates
Nicotinell/Habitrol – Novartis
Sales Estimates
Other Smoking Cessation Pharmacotherapies
Zyban (Bupropion) – GlaxoSmithKline
Sales Estimates
Future Drugs to Treat Nicotine Addiction
Late-Stage Development Product Focus
Rimonabant (Acomplia) – Sanofi-Aventis
Varenicline – Pfizer
Vaccine Focus
NicVAX – Nabi Biopharmaceuticals
TA-NIC – Xenova
Nicotine Addiction – Market Insights and Future Considerations
Drugs in the Pipe

Chapter 3 Drugs in Research and Development

Addiction Disorders: Drugs in Research and Development
Research and Development Overview
Gambling Addiction – An Emerging Research and Development Area
Nalmefene – Somaxon Pharmaceuticals

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining

Market Analysis and Therapy Forecasting
Therapy Area Forecasts
Comparative Analysis: Addiction Pharmacotherapies
Prospect Mining
Addiction Disorder Pharmacotherapy Prospects
Therapy Area Forecasts 2012 and 2020

Chapter 5 Report Synopsis
Addictions – Key Data Points
Reference Sources

List of Tables

Table 1.1 Neurotransmitter Systems Associated with Addiction
Table 1.2 Drugs of Abuse and their Associations with Neurotransmitter Systems
Table 2.1 Estimated Global Sales (US$) and Annual Growth (%) of Key Drugs to Treat Addictions, 2004-2012
Table 2.2 Physiological Consequences of the Disulfiram-Alcohol Reaction
Table 2.3 Estimated Sales (US$) and Annual Growth (%) of Smoking Cessation Therapies, 2004-2012
Table 2.4 Drugs in Development for Nicotine Addiction, 2005 (partial)
Table 3.1 Drugs in Development for Alcohol and Narcotic Addictions, 2005
Table 3.2 Drugs in Development for Nicotine Addiction, 2005
Table 4.1 Estimated Global Sales (US$) and Growth Rate (%) for Addiction Pharmacotherapies, 2004-2012
Table 4.2 Therapy Area Forecasts for the World Addiction Disorder Market, 2012 & 2020 (US$)

List of Figures

Figure 1.1 Prevalence of Alcohol, Smoking, and Illicit Drug Abuse in UK 12 and US Populations, 2002-2004
Figure 2.1 Estimated Sales (US$) of Addiction Drugs Segmented by Therapeutic Area,
2004-2012
Figure 2.3 Estimated Global Sales (US$) of Leading Addiction Drugs by Therapy Area,
2005 & 2012
Figure 4.1 Addiction Pharmacotherapy Market Forecasts, 2005 & 2012 (US$)
Figure 4.2 Comparative Analysis of Leading Addiction Pharmacotherapies,
2004-2012 (US$)
Figure 4.3 Key Addiction Disorder Drug Prospects, 2005